Experts at India's drug regulator clear the path for vaccines, trials

India's drug regulator seems to be taking into account the views of the domestic drug industry, which urged the Central Drugs Standards Control Organization (CDSCO) to consider extending the fast-track approval process adopted during COVID-19 to non-Covid drugs as well. Apart from domestic majors, multinational pharma companies, with their vaccines and drugs, also stand to benefit, reports The Pharma Letter’s India correspondent.

India's first indigenously developed mRNA vaccine has received approval for emergency use by the DCGI. The vaccine can be used for people who are 18 years and above and has been developed by Gennova Biopharmaceuticals.

The CDSCO's Subject Expert Committee (SEC), which looks into applications on vaccine approvals, also granted marketing authorization to Serum Institute of India's hexavalent vaccine, and a favorable recommendation for its quadrivalent human papillomavirus vaccine (qHPV) to treat cervical cancer.